Home > Insider Trading > Filing (0001209191-17-046462)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1479419	Kala Pharmaceuticals Inc.	KALA	()	4

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1253886	G Patrick Enright	800 El Camino Real Suite 220 Menlo Park CA 94025	No	No	Yes	No
1431159	Juliet Bakker Tammenoms	800 El Camino Real Suite 220 Menlo Park CA 94025	No	No	Yes	No
1527510	Longitude Venture Partners Ii, L.p.	800 El Camino Real Suite 220 Menlo Park CA 94025	No	No	Yes	No
1647491	Longitude Capital Partners Ii, Llc	800 El Camino Real Suite 220 Menlo Park CA 94025	No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2017-07-25	2,055,946	$0.00	2,055,946	No	4	C	Indirect	By Longitude Venture Partners II, L.P.
Common Stock	Acquisiton	2017-07-25	215,000	$15.00	2,270,946	No	4	P	Indirect	By Longitude Venture Partners II, L.P.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	By Longitude Venture Partners II, L.P.
No	4	P	Indirect	By Longitude Venture Partners II, L.P.

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series C Preferred Stock	Disposition	2017-07-25	10,707,985	$0.00	2,055,946	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Indirect

Footnotes

The Series C Preferred Stock converted into Common Stock on a 5.2083-for-one-basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
This Form 4 is filed jointly by Longitude Capital Partners II, LLC ("Longitude Capital II"), Longitude Venture Partners II, L.P. ("Longitude Venture II"), Patrick G. Enright ("Mr. Enright") and Juliet Tammenoms Bakker ("Ms. Bakker"), all of whom shared beneficial ownership of more than 10% of the capital stock of the Issuer as of the date of the transactions reported in this Form 4. Longitude Capital II is the general partner of Longitude Venture II and may be deemed to share voting and investment power over the shares held by Longitude Venture II. Mr. Enright and Ms. Bakker are the managing members of Longitude Capital II and may be deemed to share voting and investment power over the shares held by Longitude Venture II. Each of Longitude Capital II, Mr. Enright and Ms. Bakker disclaims beneficial ownership of such shares except to the extent of its, his or her pecuniary interest therein.
Longitude Venture II acquired 215,000 shares of Common Stock in the Issuer's initial public offering.